Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343626 | 0.85 | GAA (0.39) | CA12CA1CA2CA9GAA | |
| SCHEMBL1342355 | 0.82 | JAK1 (0.32) | SIRT5GAALMNAHSD17B10SMN1; SMN2 | |
| SCHEMBL12553695 | 0.80 | ESR1 (0.39) | CA12CA1CA2CA9SIRT5 | |
| SCHEMBL1342318 | 0.80 | SIRT5 (0.35) | SIRT5GAALMNAHSD17B10SMN1; SMN2 | |
| SCHEMBL12553694 | 0.80 | SIRT5 (0.31) | SIRT5GAALMNAHSD17B10SMN1; SMN2 | |
| SCHEMBL1148560 | 0.73 | PIK3CD (0.38) | SIRT5GAALMNAHSD17B10SMN1; SMN2 | |
| SCHEMBL1148455 | 0.72 | HSD11B1 (0.32) | HSD11B1HSP90AA1 | |
| SCHEMBL1148781 | 0.71 | GAA (0.39) | CA12CA1CA2CA9GAA | |
| SCHEMBL420040 | 0.70 | KDM4E (0.50) | GAALMNAHSD17B10SMN1; SMN2MAPT | |
| SCHEMBL13100013 | 0.70 | SIRT5 (0.32) | SIRT5GAALMNAHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144398-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2019-05-16 | — | — | US | disclosed |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2017-11-09 | — | — | US | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150174134-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | SYNTA PHARMACEUTICALS CORP (US) | 2015-04-02 | — | — | US | disclosed |
| US-7608635-B2 | heat shock protein 90 inhibitors; antiproliferative agents; angiogenesis inhibitors | SYNTA PHARMACEUTICALS CORP. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20070191445-A1 | heat shock protein 90 inhibitors; antiproliferative agents; angiogenesis inhibitors | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2007-08-16 | — | — | US | disclosed |
| US-20070191445-A1 | heat shock protein 90 inhibitors; antiproliferative agents; angiogenesis inhibitors | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2007-08-16 | — | — | US | disclosed |
| WO-2007021966-A1 | PYRAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191445-A1 | heat shock protein 90 inhibitors; antiproliferative agents; angiogenesis inhibitors | HSP90AB1, HSP90AA1, HSP90AB2P | CA12 4737/4885CA1 4708/4885CA2 4269/4885 |
| US-20150174134-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | CA12 3402/4885CA1 3134/4885CA2 1971/4885 |
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | HSP90AB1, HSP90AB2P, HSP90AA1 | CA12 4122/4885CA1 4784/4885CA2 3305/4885 |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | HSP90AB1, HSP90AB2P, HSP90B1 | CA12 2595/4885CA1 2868/4885CA2 3209/4885 |
| US-20190144398-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | CA12 752/4885CA1 1638/4885CA2 1747/4885 |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | CA12 752/4885CA1 1638/4885CA2 1747/4885 |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | HSP90AB1, HSP90AB2P, HSP90AA1 | CA12 4122/4885CA1 4784/4885CA2 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.